Effects of resistant starch on glycemic control, serum lipoproteins and systemic inflammation in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled clinical trials by Halajzadeh, Jamal et al.
REVIEW
Effects of resistant starch on glycemic control, serum lipoproteins and systemic
inflammation in patients with metabolic syndrome and related disorders:
A systematic review and meta-analysis of randomized controlled clinical trials
Jamal Halajzadeha, Alireza Milajerdib,c, Zeljko Reinerd, Elaheh Amiranie, Fariba Kolahdoozf, Maryam Barekatg,
Hamed Mirzaeie, Seyyed Mehdi Mirhashemih, and Zatollah Asemie
aDepartment of Biochemistry and Nutrition, Research Center for Evidence-Based Health Management, Maraghe University of Medical
Science, Maraghe, Iran; bStudents’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran; cDepartment of
Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran; dDepartment of
Internal Medicine, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia; eResearch Center for
Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran; fIndigenous and Global Health
Research, Department of Medicine, University of Alberta, Edmonton, Canada; gDepartment of Regenerative Biomedicine, Cell Science
Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; hMetabolic Diseases Research Center, Research
Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
ABSTRACT
The aim of this systematic review and meta-analysis was to evaluate the effects of resistant starch
(RS) on glycemic status, serum lipoproteins and inflammatory markers in patients with metabolic
syndrome (MetS) and related disorders. Two independent authors systematically searched online
database including EMBASE, Scopus, PubMed, Cochrane Library, and Web of Science from incep-
tion until 30 April 2019. Cochrane Collaboration risk of bias tool was applied to assess the meth-
odological quality of included trials. The heterogeneity among the included studies was assessed
using Cochrane’s Q test and I-square (I2) statistic. Data were pooled using a random-effects model
and weighted mean difference (WMD) was considered as the overall effect size. Nineteen trials
were included in this meta-analysis. Administration of RS resulted in significant reduction in fasting
plasma glucose (FPG) (14 studies) (WMD: 4.28; 95% CI: 7.01, 1.55), insulin (12 studies) (WMD:
1.95; 95% CI: 3.22, 0.68), and HbA1C (8 studies) (WMD: 0.60; 95% CI: 0.95, 0.24). When
pooling data from 13 studies, a significant reduction in total cholesterol levels (WMD: 8.19; 95%
CI: 15.38, 1.00) and LDL-cholesterol (WMD: 8.57; 95% CI: 13.48, 3.66) were found as well.
Finally, RS administration was associated with a significant decrease in tumor necrosis factor alpha
(TNF-a) (WMD: 2.02; 95% CI: 3.14, 0.90). This meta-analysis showed beneficial effects of RS on
improving FPG, insulin, HbA1c, total cholesterol, LDL-cholesterol and TNF-a levels in patients with









Currently, growing evidence suggests that intestinal micro-
flora plays as important role in the development of meta-
bolic disorders such as dyslipidemia, insulin resistance and
inflammation (Panwar et al. 2013; Shen, Obin, and Zhao
2013). Microflora is defined as microorganisms that live
within the human bodies (more than 2000 species of com-
mensal bacterial organisms) (Neish 2009). Digestive tract is
the most important part of the body where these microor-
ganisms, especially bacteria, live. Many microorganisms,
mostly gut microflora, have an influence on the function of
human body by different mechanisms such as immunomo-
dulation, protection by formation of physical barriers, anti-
inflammatory by production of short chain fatty acids
(SCFA), and production of bacteriocins (Montalto et al.
2009). Changes in composition of gut microflora can have
beneficial or unfavorable effects on the health of the host
organism. Diet is one of many factors that can cause persist-
ence of a specific bacteria in the digestive tract (Panwar
et al. 2013; Sekirov et al. 2010).
Resistant starch (RS) is defined as “selectively fermented
ingredients that result in specific changes in the composition
and/or activity of the gastrointestinal microbiota, thus con-
ferring benefits upon host health” (Gibson et al. 2010). RS is
a fraction of starch which is resistant to digestive enzymes
in small intestine and is delivered intact to colon to be fer-
mented by bacteria. RS divided into five subtypes (RS1-RS5)
based on their structure and sources (Homayouni et al.
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